Arcellx Inc
NASDAQ:ACLX
Arcellx Inc
Revenue
Arcellx Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Arcellx Inc
NASDAQ:ACLX
|
Revenue
$107.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Arcellx Inc
Glance View
In the bustling landscape of biotechnology, where innovation is the keystone of success, Arcellx Inc. charts an intriguing path. It operates at the cutting edge of medical science, specializing in the development of engineered immunotherapies for the treatment of cancer and other serious diseases. The company's core technology pivots around its proprietary ARC-SparX platform, a modular antibody-recruiting platform designed to enhance the targeting and activation of T-cells against malignant cells. By engineering these immune cells to specifically recognize and attack cancer, Arcellx endeavors to transcend the traditional boundaries of oncology treatment, offering a more personalized and effective therapeutic approach. Arcellx's financial engine is powered by the potential success of its therapies in development, as well as strategic partnerships and licensing agreements. In the biopharma realm, revenue generation often hinges on the successful progression of clinical trials and the eventual approval and commercialization of its products. For Arcellx, this means advancing its pipeline through rigorous clinical phases while also engaging in collaborations with larger pharmaceutical entities. These partnerships not only offer monetary infusions but also extend the reach of Arcellx's innovative therapies, thus amplifying their commercial potential. Through this strategic blueprint, Arcellx positions itself to capture a share of the lucrative oncology market, all while endeavoring to revolutionize patient care through its scientific innovations.
See Also
What is Arcellx Inc's Revenue?
Revenue
107.9m
USD
Based on the financial report for Dec 31, 2024, Arcellx Inc's Revenue amounts to 107.9m USD.
What is Arcellx Inc's Revenue growth rate?
Revenue CAGR 1Y
-2%
Over the last year, the Revenue growth was -2%.
You don't have any saved screeners yet